Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Elafibranor 80 mg in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)

NCT06730061 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT06730061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06730061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Elafibranor 80 mg in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 16, 2025
Completion date
April 8, 2032
Enrollment
18 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

primary biliary cholangitis